乳腺癌(BC)显著影响受影响个体的生活质量(QoL)。这项研究,在科尔埃亚临床医院进行,布加勒斯特,旨在使用EORTCQLQ-C30和EORTCQLQ-BR45问卷评估器官衰竭和转移对乳腺癌患者QoL的影响以及生存率,以了解乳腺癌患者的临床旅程和生活质量状况。从2019年1月到2022年10月,观察性研究调查了874名患者,有201人死亡,66个拒绝,和607名合格参与者。结果表明,心力衰竭患者在各种QoL方面存在统计学上的显着差异,包括身体功能,疼痛,失眠,全球健康状况,和总体总结得分。肾衰竭在QLQ-C30和身体形象的身体功能方面表现出重要意义,性功能,以及QLQ-BR45的内分泌性症状。呼吸衰竭在多个QoL领域表现出显著差异。骨转移患者的身体功能降低(p=0.006)和疼痛增加(p=0.002)。这项研究显示,总体5年预期寿命为68.8%,Ⅰ期生存率为93.8%,第二阶段为86.3%,III期乳腺癌为77.2%。转移性癌症患者在45个月内的生存率为35.6%,中位生存期为36个月。我们研究的一个显著限制是问卷的管理只有一次,阻止我们量化特定治疗类型对生活质量的影响。这项研究强调了从最初的陈述到持续的随访,在临床实践中使用标准化的QoL评估的必要性。
Breast cancer (BC) significantly impacts the quality of life (QoL) of affected individuals. This
study, conducted at Colțea Clinical Hospital, Bucharest, aimed to assess the impact of organ failures and metastases on QoL in breast cancer patients using EORTC QLQ-C30 and EORTC QLQ-BR45 questionnaires and the survival rate to understand the clinical journey and the quality of life status in breast cancer patients. From January 2019 to October 2022, a prospective, observational
study surveyed 874 patients, revealing 201 fatalities, 66 refusals, and 607 eligible participants. Results indicated statistically significant differences in various QoL aspects for patients experiencing heart failure, including physical functioning, pain, insomnia, global health status, and overall summary score. Kidney failure exhibited significance in physical functioning for QLQ-C30 and body image, sexual functioning, and endocrine sexual symptoms for QLQ-BR45. Respiratory failure demonstrated significant differences across multiple QoL domains. Patients with bone metastases reported lower physical functioning (p = 0.006) and increased pain (p = 0.002). This
study has revealed an overall 5-year life expectancy of 68.8%, with survival rates of 93.8% for Stage I, 86.3% for Stage II, and 77.2% for Stage III breast cancer. Metastatic cancer patients have shown a 35.6% survival rate over 45 months, with a median survival duration of 36 months. A significant limitation of our
study was the administration of the questionnaire only once, preventing us from quantifying the impact of specific treatment types on quality of life. This
study emphasizes the necessity of using standardized QoL assessments in clinical practice from the initial presentation to ongoing follow-up.